The effectiveness of inferior vena cava filter (IVCF) insertion in reducing venous thromboembolism (VTE)-associated morbidity and mortality is uncertain. 415.11, 415.13, 415.19) were also identified during the study period. We determined the rates of IVCF implantation, and VTE-related hospitalizations per 100 000 US population, using annual census data provided by the US Census Bureau. Temporal trends were assessed using Cochran-Armitage test (SPSS software, version 22.0; IBM Corp).
Results | An estimated 1 131 274 patients underwent IVCF placement over the 10-year study period (Figure 1 ). Figure 2 , the temporal trends in VTE hospitalizations do not explain the significant reduction in IVCF implantation rates. It has been previously suggested that the decline in the rates of IVCF placement in the United States was a result of decreased reimbursement for this procedure by the way of bundling the associated Current Procedural Terminology (CPT) codes. Despite the significant reduction in IVCF use following the FDA advisory, implantation rates across the United States remain high. Given the short-and long-term complications associated with IVCF placement, the use of these devices should be mostly reserved for those patients with an absolute indication like active bleeding. Because the rate of IVCF implantation in 5 large European countries is less than 3 per 100 000 population, we believe that the appropriate implantation rate in the United States should be similar to or lower than the rate observed in Europe.
